A detailed history of Captrust Financial Advisors transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Captrust Financial Advisors holds 24,033 shares of HALO stock, worth $1.1 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
24,033
Previous 26,363 8.84%
Holding current value
$1.1 Million
Previous $1.38 Million 0.43%
% of portfolio
0.0%
Previous 0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$51.3 - $64.42 $119,529 - $150,098
-2,330 Reduced 8.84%
24,033 $1.37 Million
Q2 2024

Aug 14, 2024

SELL
$37.81 - $52.4 $14,443 - $20,016
-382 Reduced 1.43%
26,363 $1.38 Million
Q1 2024

May 15, 2024

SELL
$33.68 - $41.95 $23,946 - $29,826
-711 Reduced 2.59%
26,745 $1.09 Million
Q4 2023

Feb 14, 2024

BUY
$33.32 - $42.1 $35,085 - $44,331
1,053 Added 3.99%
27,456 $1.01 Million
Q3 2023

Nov 14, 2023

BUY
$36.46 - $44.03 $962,653 - $1.16 Million
26,403 New
26,403 $1.01 Million
Q4 2022

Feb 15, 2023

BUY
$40.06 - $59.44 $184,516 - $273,780
4,606 New
4,606 $262,000
Q2 2022

Aug 16, 2022

BUY
$37.35 - $48.3 $19,720 - $25,502
528 Added 15.65%
3,902 $172,000
Q1 2022

May 16, 2022

BUY
$31.97 - $41.06 $4,060 - $5,214
127 Added 3.91%
3,374 $135,000
Q4 2021

Feb 14, 2022

BUY
$31.82 - $40.75 $11,105 - $14,221
349 Added 12.04%
3,247 $131,000
Q3 2021

Nov 16, 2021

BUY
$38.47 - $46.42 $12,041 - $14,529
313 Added 12.11%
2,898 $118,000
Q2 2021

Aug 16, 2021

SELL
$38.84 - $51.31 $116 - $153
-3 Reduced 0.12%
2,585 $117,000
Q1 2021

May 17, 2021

BUY
$39.51 - $51.45 $25,009 - $32,567
633 Added 32.38%
2,588 $108,000
Q4 2020

Feb 16, 2021

BUY
$25.81 - $43.62 $6,581 - $11,123
255 Added 15.0%
1,955 $83,000
Q2 2020

Aug 14, 2020

BUY
$16.25 - $26.81 $27,625 - $45,577
1,700 New
1,700 $47,000
Q4 2019

Feb 14, 2020

SELL
$14.93 - $19.53 $25,381 - $33,201
-1,700 Closed
0 $0
Q3 2018

Nov 15, 2018

BUY
$16.68 - $18.41 $28,356 - $31,297
1,700 New
1,700 $31,000

Others Institutions Holding HALO

About HALOZYME THERAPEUTICS, INC.


  • Ticker HALO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 139,288,992
  • Market Cap $6.37B
  • Description
  • Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...
More about HALO
Track This Portfolio

Track Captrust Financial Advisors Portfolio

Follow Captrust Financial Advisors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Captrust Financial Advisors, based on Form 13F filings with the SEC.

News

Stay updated on Captrust Financial Advisors with notifications on news.